Manufacturer of Vigabatrin

Vigabatrin (Vigabatrin), sold under the brand name Sabril, is a drug used to treat epilepsy. It became a generic drug in 2019 and was originally developed by Sanofi Pharmaceuticals. It works by inhibiting the breakdown of gamma-aminobutyric acid (GABA). Also known as gamma-vinyl GABA, it is a structural analog of GABA but does not bind to GABA receptors.

Vibatrin is consideredAs an adjunctive treatment (i.e., not for first-line treatment) of refractory complex partial epilepsy 2 years of age and older who have had an inadequate response to multiple treatments, and as a monotherapy for infantile spasms in patients 1 month to 2 years of age, for whom the potential benefits outweigh the risk of vision loss. Vigabatrin is an antiepileptic drug that is chemically unrelated to other anticonvulsant drugs. It blocks the metabolism of GABA by irreversibly inhibiting GABA transaminase (GABA-T). Its duration of action is thought to depend on the rate of GABA-T resynthesis rather than the rate of drug elimination.

The original Vigabatrin drug has not yet been launched in China, so it is not included in medical insurance. The Hong Kong version of the specificationsThe price of 500mg*100 bags per box may be more than 1,000 yuan (the price may fluctuate due to exchange rate effects). It is reported that an Indian chemical generic drug vigabatrin powder is on the domestic market. The price of each box of 500mg*50 bags may be more than 3,000 yuan. Its pharmaceutical ingredients are basically the same as those of the original drug. The Turkish version of Vigabatrin currently sold overseas may cost more than RMB 1,000 per box of 500mg*100 bags (the price may fluctuate due to exchange rates).